Methods and compositions for the treatment of neuropsychiatric disorders
OwnerJay L. LOMBARDinventor
Life of this patent
Estimating the term…
Abstract
Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and/or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and/or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions.
Claims30
A method of treating a patient having a disruption in a prefrontal dopamine axis (Axis I) with a medical food, the method comprising providing the patient with a medical food composition comprising a first compound that reduces degradation of dopamine and a second compound that increases synthesis of dopamine.
A method of treating a patient having a disruption in a prefrontal dopamine axis (Axis I) with a medical food, the method comprising:
- determining that the patient has a disruption in the prefrontal dopamine axis based on the presence of one or more biomarkers indicating a disruption in the prefrontal dopamine axis;
- and
- providing the patient with a medical food composition comprising phosphatidylserine and methylfolate that reduces degradation of dopamine and increases synthesis of dopamine.
A method of treating a patient having a disruption in a limbic hyperactivity (Axis II) with a medical food, the method comprising providing the patient with a medical food composition comprising a first compound that increases brain mitochondrial activity and a second compound that increases the degradation and/or reuptake of catecholamines.
A method of treating a patient having a disruption in a limbic hyperactivity axis (Axis II) with a medical food, the method comprising:
- determining that the patient has a disruption in the limbic hyperactivity axis based on the presence of one or more biomarkers indicating a disruption in the prefrontal dopamine axis;
- and
- providing the patient with a medical food composition comprising a creatine, magnesium and taurine configured to increase brain mitochondrial activity and increase the degradation and/or reuptake of catecholamines.
A method of treating a patient having a disruption in a cortical glutamate axis (Axis III) with a medical food, the method comprising providing the patient with a medical food composition comprising a combination of compounds that inhibits PLA2, reduces NMDA neurotoxicity and enhances BDNF function.
A method of treating a patient having a disruption in a cortical glutamate axis (Axis III) with a medical food, the method comprising:
- determining that the patient has a disruption in the cortical glutamate axis based on the presence of one or more biomarkers indicating a disruption in the calcium-dependent NMDA transmission;
- and
- providing the patient with a medical food composition comprising a combination of compounds that inhibits PLA2, reduces NMDA neurotoxicity and enhances BDNF function, the combination comprising docosahexaenoic acid (DHA) and cytidine diphosphate choline.
A method of treating a patient having a disruption in a subcortical glutamate axis (Axis IV) with a medical food, the method comprising providing a biomarkers indicating an excess of glutamate or a deficiency of dopamine in a subcortical region with a medical food composition comprising sulphoraphane and N-acetylcysteine.
A method of treating a patient having a disruption in a subcortical glutamate axis (Axis IV) with a medical food, the method comprising:
- determining that the patient has a disruption in the subcortical glutamate axis based on the presence of one or more biomarkers indicating an excess of glutamate or a deficiency of dopamine in a subcortical region comprising a polymorphism in one or more of SLC1A1, OPRM1 and DBH genes;
- and
- providing the patient with a medical food composition comprising sulphoraphane at a dose of between about 5 and about 70 mg/daily and N-acetylcysteine at a dose of between about 500 and about 2400 mg/daily.
Dependencies are inferred from the claim text.